Combinations of ibuprofen with aztreonam and ceftazidime display synergistic antimicrobial activity against drug-resistant Pseudomonas aeruginosa isolates in vitro, and efficacy of ceftazidime combined with ibuprofen was shown in vivo in a murine P aeruginosa pneumonia model, according to research presented at American Society of Microbiology (ASM) Microbe 2019 held from June 20-24, 2019 in San Francisco, California.
Approximately 50% of the lungs of patients with cystic fibrosis have detectable P aeruginosa, and 20% of adults with cystic fibrosis hold multi-drug resistant isolates that have limited treatment options.